Published in Can J Cardiol on February 01, 2009
Mononuclear cell secretome protects from experimental autoimmune myocarditis. Eur Heart J (2013) 1.45
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Underrepresentation of individuals 80 years of age and older in chronic disease clinical practice guidelines. Can Fam Physician (2011) 1.09
Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. J Cardiovasc Magn Reson (2012) 0.90
A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. Case Rep Med (2009) 0.90
An Internet-Based Counseling Intervention With Email Reminders that Promotes Self-Care in Adults With Chronic Heart Failure: Randomized Controlled Trial Protocol. JMIR Res Protoc (2014) 0.85
Acute myocarditis mimicking ST-elevation myocardial infarction: A case report and review of the literature. Exp Ther Med (2015) 0.80
Noninvasive risk stratification after myocardial infarction: rationale, current evidence and the need for definitive trials. Can J Cardiol (2009) 0.79
Role of cardiac MRI and nuclear imaging in cardiac resynchronization therapy. Nat Rev Cardiol (2009) 0.78
Effective communication and ethical consent in decisions related to ICDs. Nat Rev Cardiol (2011) 0.75
Predictors of implantable cardioverter-defibrillator use in patients with ischemic cardiomyopathy. Open Cardiovasc Med J (2010) 0.75
A Challenging Case Of Ventricular Arrhythmia In A Patient With Myocarditis: ICD Yes/No After Ablation. J Atr Fibrillation (2014) 0.75
Beta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin. Open Cardiovasc Med J (2014) 0.75
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation (1999) 8.13
Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J (2004) 7.84
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation (2008) 7.11
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med (2004) 6.55
Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol (2009) 6.41
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol (2007) 6.12
Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 6.01
Retracted Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet (2007) 5.17
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation (2006) 4.69
Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation (2001) 4.38
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA (2007) 4.25
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation (2007) 3.97
The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol (2005) 3.85
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet (1999) 3.81
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation (2008) 3.63
Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med (2007) 3.61
Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA (2002) 3.60
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation (1999) 3.25
Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation (2008) 3.25
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol (2007) 3.09
Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation (2005) 2.94
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA (2007) 2.93
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA (2007) 2.90
B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation (2002) 2.85
Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med (2006) 2.84
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest (2007) 2.67
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol (2008) 2.66
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol (2005) 2.62
Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation (2007) 2.58
Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation (2007) 2.56
Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation (2003) 2.56
The etiologic spectrum of constrictive pericarditis. Am Heart J (1987) 2.34
Diagnosis of myocarditis: death of Dallas criteria. Circulation (2006) 2.30
Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol (2004) 2.27
CT and MR imaging of pericardial disease. Radiographics (2003) 2.19
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol (2007) 2.15
Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol (2007) 2.12
Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease. Eur Heart J (1996) 2.11
Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol (2003) 2.09
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail (1997) 2.08
Biopsy-induced tricuspid regurgitation after cardiac transplantation. Ann Thorac Surg (1994) 2.07
Myocarditis: the Dallas criteria. Hum Pathol (1987) 2.05
Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation (2003) 2.01
Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation (2004) 2.00
Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med (1985) 1.99
Task Force 8: classification of sports. J Am Coll Cardiol (2005) 1.94
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91
The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol (2005) 1.83
HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm (2008) 1.79
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. J Am Coll Cardiol (2006) 1.67
Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J (2007) 1.67
Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res (2008) 1.62
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation (1992) 1.61
Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation (1996) 1.59
Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 1.58
Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol (2000) 1.57
The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart (2001) 1.51
Pacemaker lead related tricuspid stenosis: a report of two cases. Heart (2000) 1.50
Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet (1987) 1.49
B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med (2002) 1.48
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med (2008) 1.45
The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol (2007) 1.45
Mechanical circulatory support for patients with acute-fulminant myocarditis. Ann Thorac Surg (2001) 1.42
Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr (2007) 1.42
Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol (2004) 1.41
Constrictive pericarditis in the modern era: novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll Cardiol (2008) 1.39
Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol (2007) 1.37
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
A meta-analysis of the association between adherence to drug therapy and mortality. BMJ (2006) 7.79
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med (2014) 6.73
Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol (2009) 6.41
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care (2005) 4.78
Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med (2004) 4.72
Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med (2008) 4.64
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet (2013) 4.58
Self-denigration in pharmacy: Words to banish from the pharmacy lexicon / Autodénigrement en pharmacie : mots à bannir du vocabulaire des pharmaciens. Can Pharm J (Ott) (2014) 4.19
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res (2004) 3.93
A trial of an impedance threshold device in out-of-hospital cardiac arrest. N Engl J Med (2011) 3.76
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol (2007) 3.23
A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med (2008) 3.21
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Pilot study of an Internet patient-physician communication tool for heart failure disease management. J Med Internet Res (2005) 3.12
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
Guidelines for pharmacists integrating into primary care teams. Can Pharm J (Ott) (2013) 3.05
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol (2012) 3.03
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol (2012) 2.96
Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation (2013) 2.90
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol (2008) 2.89
Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol (2012) 2.77
Effect of fish oil on arrhythmias and mortality: systematic review. BMJ (2008) 2.76
Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation (2004) 2.74
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm (2012) 2.65
Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ (2005) 2.57
Capturing outcomes of clinical activities performed by a rounding pharmacist practicing in a team environment: the COLLABORATE study [NCT00351676]. Med Care (2009) 2.56
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology (2013) 2.56
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ (2004) 2.55
Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med (2008) 2.55
Self-denigration in pharmacy: Actions that should be curtailed. Can Pharm J (Ott) (2014) 2.51
Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail (2013) 2.50
A ciliopathy complex at the transition zone protects the cilia as a privileged membrane domain. Nat Cell Biol (2011) 2.43
Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J (2005) 2.39
Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex ≥120 milliseconds. Circulation (2011) 2.36
Does performance-based remuneration for individual health care practitioners affect patient care?: a systematic review. Ann Intern Med (2012) 2.35
Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med (2011) 2.34
Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg (2002) 2.31
Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation (2011) 2.30
Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation (2013) 2.30
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging (2008) 2.24
Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis. J Thorac Cardiovasc Surg (2007) 2.24
Pharmaceutical care in community pharmacies: practice and research in Canada. Ann Pharmacother (2005) 2.22
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J (2004) 2.20
Collaboration between pharmacists, physicians and nurse practitioners: a qualitative investigation of working relationships in the inpatient medical setting. J Interprof Care (2009) 2.19
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol (2002) 2.19
The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology (2002) 2.17
Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation (2003) 2.16
Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol (2007) 2.15
Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail (2012) 2.13
Cardiac electrophysiological consequences of neuromuscular incapacitating device discharges. J Am Coll Cardiol (2006) 2.11
Identification of an apical Cl(-)/HCO3(-) exchanger in the small intestine. Am J Physiol Gastrointest Liver Physiol (2002) 2.09
Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J (2002) 2.09
Validity and reliability of the Edmonton Frail Scale. Age Ageing (2006) 2.08
Mobile phone-based telemonitoring for heart failure management: a randomized controlled trial. J Med Internet Res (2012) 2.06
Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol (2006) 2.06
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05
Stories from the trenches: Experiences of Alberta pharmacists in obtaining additional prescribing authority. Can Pharm J (Ott) (2012) 2.04
Highly sensitized patients in cardiac transplantation: early outcomes from the Canadian Prioritized Organ Sharing Program. J Heart Lung Transplant (2012) 2.01
Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am J Physiol Heart Circ Physiol (2002) 2.00
Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation (2008) 1.98
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail (2011) 1.93